Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Klapper

Showing results (1051-1060 of 1,153) with videos related to

Pageof 116
Sort By:
Cancer Research|November 3, 2006
Chromosomal breakpoints affecting immunoglobulin loci are recurrent in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphomaJosé I Martín-Subero, Wolfram Klapper, Anna Sotnikova, et al.
Histopathology|February 28, 2023
Lack of reproducibility of histopathological features in MYC-rearranged large B cell lymphoma using digital whole slide images: a study from the Lunenburg lymphoma biomarker consortiumYasodha Natkunam, Daphne de Jong, Pedro Farinha, et al.
Science (New York, N.Y.)|May 4, 2023
Natural products from reconstructed bacterial genomes of the Middle and Upper PaleolithicMartin Klapper, Alexander Hübner, Anan Ibrahim, et al.
Blood|December 21, 2012
CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphomaItziar Salaverria, Cristina Royo, Alejandra Carvajal-Cuenca, et al.
Virchows Archiv : an International Journal of Pathology|February 2, 2021
Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic featuresSietse M Aukema, Giorgio A Croci, Susanne Bens, et al.
Blood|October 28, 2020
Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1Sarah Reinke, Paul J Bröckelmann, Ingram Iaccarino, et al.
Blood Advances|July 29, 2021
Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphomaJonathan C Strefford, Malgorzata Nowicka, Chantal E Hargreaves, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2015
Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges AheadVéronique Minard-Colin, Laurence Brugières, Alfred Reiter, et al.
The Lancet. Oncology|May 25, 2016
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trialBarbara Eichhorst, Anna-Maria Fink, Jasmin Bahlo, et al.
Oncotarget|June 25, 2016
Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancerClara Andradas, Sandra Blasco-Benito, Sonia Castillo-Lluva, et al.
Pageof 116

Showing results (1051-1060 of 1,153) with videos related to

Sort By:
Pageof 116
Cancer Research|November 3, 2006
Chromosomal breakpoints affecting immunoglobulin loci are recurrent in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphomaJosé I Martín-Subero, Wolfram Klapper, Anna Sotnikova, et al.
Histopathology|February 28, 2023
Lack of reproducibility of histopathological features in MYC-rearranged large B cell lymphoma using digital whole slide images: a study from the Lunenburg lymphoma biomarker consortiumYasodha Natkunam, Daphne de Jong, Pedro Farinha, et al.
Science (New York, N.Y.)|May 4, 2023
Natural products from reconstructed bacterial genomes of the Middle and Upper PaleolithicMartin Klapper, Alexander Hübner, Anan Ibrahim, et al.
Blood|December 21, 2012
CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphomaItziar Salaverria, Cristina Royo, Alejandra Carvajal-Cuenca, et al.
Virchows Archiv : an International Journal of Pathology|February 2, 2021
Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic featuresSietse M Aukema, Giorgio A Croci, Susanne Bens, et al.
Blood|October 28, 2020
Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1Sarah Reinke, Paul J Bröckelmann, Ingram Iaccarino, et al.
Blood Advances|July 29, 2021
Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphomaJonathan C Strefford, Malgorzata Nowicka, Chantal E Hargreaves, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2015
Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges AheadVéronique Minard-Colin, Laurence Brugières, Alfred Reiter, et al.
The Lancet. Oncology|May 25, 2016
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trialBarbara Eichhorst, Anna-Maria Fink, Jasmin Bahlo, et al.
Oncotarget|June 25, 2016
Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancerClara Andradas, Sandra Blasco-Benito, Sonia Castillo-Lluva, et al.
Pageof 116